0000874716-23-000117.txt : 20230905 0000874716-23-000117.hdr.sgml : 20230905 20230905170120 ACCESSION NUMBER: 0000874716-23-000117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230831 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MAZELSKY JONATHAN JAY CENTRAL INDEX KEY: 0001556270 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19271 FILM NUMBER: 231236691 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092 FORMER NAME: FORMER CONFORMED NAME: MAZELSKY JAY DATE OF NAME CHANGE: 20120815 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE CENTRAL INDEX KEY: 0000874716 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010393723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 BUSINESS PHONE: 2075560300 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 FORMER COMPANY: FORMER CONFORMED NAME: IDEXX CORP / DE DATE OF NAME CHANGE: 19600201 4 1 wk-form4_1693947669.xml FORM 4 X0508 4 2023-08-31 0 0000874716 IDEXX LABORATORIES INC /DE IDXX 0001556270 MAZELSKY JONATHAN JAY ONE IDEXX DRIVE WESTBROOK ME 04092 1 1 0 0 President and CEO 0 Common Stock 2023-08-31 4 M 0 13424 79.54 A 86349.3456 D Common Stock 2023-08-31 4 S 0 13424 512.0133 D 72925.3456 D Non-Qualified Stock Option (right-to-buy) 79.54 2023-08-31 4 M 0 13424 D 2025-02-13 Common Stock 13424 13424 D Represents the weighted average price of the shares sold ranging from a low of $512.00 to a high of $512.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Grant of option to buy 13,424 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Not applicable. /s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky 2023-09-05